Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Amifostine in Myelodysplastic Syndromes
NCT00005598Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Oct 2000
- Primary completion
- Dec 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine, amifostine in myelodysplastic syndrome (MDS), sponsored by University of Michigan Rogel Cancer Center. Started Oct 2000; status: completed.
02
Drugs
azacitidineamifostine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00005598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005598.